GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 229 filers reported holding GENMAB A/S in Q3 2023. The put-call ratio across all filers is 1.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $213,198 | -3.6% | 5,609 | -4.2% | 0.02% | -5.9% |
| Q1 2023 | $221,085 | -20.6% | 5,855 | -10.9% | 0.02% | -26.1% |
| Q4 2022 | $278,352 | +42.0% | 6,568 | +7.5% | 0.02% | +21.1% |
| Q3 2022 | $196,000 | -0.5% | 6,107 | +0.6% | 0.02% | 0.0% |
| Q2 2022 | $197,000 | -27.6% | 6,068 | -19.3% | 0.02% | -17.4% |
| Q1 2022 | $272,000 | +11.0% | 7,516 | +21.1% | 0.02% | +4.5% |
| Q4 2021 | $245,000 | -11.6% | 6,205 | -2.0% | 0.02% | -18.5% |
| Q3 2021 | $277,000 | +19.9% | 6,330 | +11.8% | 0.03% | +17.4% |
| Q2 2021 | $231,000 | +54.0% | 5,664 | +23.8% | 0.02% | +27.8% |
| Q1 2021 | $150,000 | +23.0% | 4,575 | +52.7% | 0.02% | 0.0% |
| Q4 2020 | $122,000 | +121.8% | 2,997 | +98.1% | 0.02% | +80.0% |
| Q3 2020 | $55,000 | +511.1% | 1,513 | +477.5% | 0.01% | +400.0% |
| Q2 2020 | $9,000 | +800.0% | 262 | +571.8% | 0.00% | – |
| Q1 2020 | $1,000 | – | 39 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 52,148 | $1,839,260 | 1.67% |
| Ativo Capital Management LLC | 28,442 | $1,003,132 | 1.13% |
| HARDING LOEVNER LP | 3,204,230 | $113,013,183 | 0.75% |
| Hardman Johnston Global Advisors LLC | 592,318 | $20,891,056 | 0.70% |
| Yorktown Management & Research Co Inc | 16,600 | $585,482 | 0.66% |
| TORRAY INVESTMENT PARTNERS LLC | 104,516 | $3,686,279 | 0.65% |
| First Light Asset Management, LLC | 157,147 | $5,542,575 | 0.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,300 | $1,561,575 | 0.53% |
| Capricorn Fund Managers Ltd | 37,007 | $1,305,237 | 0.45% |
| Legacy Wealth Asset Management, LLC | 29,496 | $1,040,324 | 0.38% |